Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical ...

Glecirasib, a KRAS G12C inhibitor by Jacobio Pharmaceuticals, shows promise in treating KRAS G12C mutant cancers with high selectivity and low gastrointestinal toxicity. Clinical trials demonstrate significant efficacy in NSCLC and pancreatic cancer, with ongoing studies exploring its potential in various solid tumors and combination therapies.